¼¼°èÀÇ ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀå : Áúȯ À¯Çüº°, Ä¡·á À¯Çüº°, Á¦Çüº°, Åõ¿© °æ·Îº°, ¿¬·ÉÃþº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Coagulation Factor Deficiency Market, By Disorder Type, By Treatment Type, By Dosage Form, By Route of Administration, By Age Group, By End User, By Geography
»óǰÄÚµå : 1789370
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,319,000
Unprintable PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,830,000
PDF & Excel (Multi User License - Up to 7 Users) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ÃÖ´ë 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,044,000
PDF & Excel (Corporate User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀåÀº 2025³â¿¡´Â 50¾ï 1,000¸¸ ´Þ·¯, 2032³â¿¡´Â 89¾ï ´Þ·¯¿¡ À̸£°í, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 8.2%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

ºÐ¼® ¹üÀ§ ºÐ¼® »ó¼¼
±âÁØ ¿¬µµ 2024³â ½ÃÀå ±Ô¸ð(2025³â) 50¾ï 1,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ CAGR(2025-2032³â) 8.20% ¿¹Ãø ±Ý¾×(2032³â) 89¾ï ´Þ·¯

¼¼°è ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀåÀº Èñ±ÍÇÏÁö¸¸ »ý¸íÀ» À§ÇùÇÏ´Â À¯Àü¼º ÃâÇ÷¼º ÁúȯÀ¸·Î Á¤»óÀûÀÎ ÁöÇ÷¿¡ ÇʼöÀûÀΠƯÁ¤ ÀÀ°íÀÎÀÚÀÇ °á¼Õ ¶Ç´Â ±â´É Àå¾Ö¸¦ Ư¡À¸·Î ÇÏ´Â ±¤¹üÀ§ÇÑ Ç÷¾×ÇÐ Ä¡·áÁ¦ Áß Áß¿äÇÑ ºÎ¹®ÀÔ´Ï´Ù. ÀÀ°íÀÎÀÚ °áÇÌÁõ¿¡´Â Ç÷¿ìº´ A(Á¦8ÀÎÀÚ °áÇÌÁõ), Ç÷¿ìº´ B(Á¦9ÀÎÀÚ °áÇÌÁõ), ±×¸®°í Á¦ I, II, V, VII, X, XI, XIII ÀÎÀÚ¸¦ Æ÷ÇÔÇÑ Èñ±Í °áÇÌÁõÀÌ ÀÖÀ¸¸ç, Àü ¼¼°èÀûÀ¸·Î ¾à 40¸¸ ¸íÀÌ ¾Î°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ÁúȯÀº ÃâÇ÷ ¿¡ÇǼҵåÀÇ Àå±âÈ­, ÀÚ¿¬ ÃâÇ÷, ¼ö¼úÀÇ À§Çè Áõ°¡·Î ³ªÅ¸³ª¸ç, ÀÎÀÚ º¸Ãæ ¿ä¹ý, ¿¹¹æÀû Ä¡·á, »õ·Î¿î À¯ÀüÀÚ Ä¡·á¸¦ ÅëÇÑ Æò»ý °ü¸®°¡ ÇÊ¿äÇÕ´Ï´Ù. µ¿ ½ÃÀåÀº ±â¼úÀÇ ¹ßÀü°ú ÀÀ°í ij½ºÄÉÀÌµå ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ÀÌÇØÀÇ Çâ»óÀ¸·Î Ç÷Àå À¯·¡ ³óÃàÁ¦Á¦¿¡¼­ ÀçÁ¶ÇÕ ÀÎÀÚ Á¦Á¦ ¹× ¹Ý°¨±â ¿¬Àå Á¦Á¦·Î Å©°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀÇ ÀÎ½Ä Á¦°í, Áø´Ü ´É·Â Çâ»ó, ȯÀÚ µî·Ï °³¼±, ½ÅÈï±¹ ½ÃÀå¿¡¼­ÀÇ Àü¹® ÀÇ·á ¼­ºñ½º Á¢±Ù¼º È®´ë µîÀÌ ½ÃÀå °³Ã´¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºñÀÎÀÚ ¿ä¹ý, ÇÇÇÏÁÖ»ç, À¯ÀüÀÚ ÆíÁý ±â¼ú µî Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀ¸·Î Ä¡·á ȯ°æÀº °è¼Ó º¯È­Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¸¸¼º Áúȯ¿¡ µû¸¥ °æÁ¦Àû ºÎ´ãÀ» ÇØ¼ÒÇϰí ȯÀÚÀÇ ÆíÀǼº Çâ»ó°ú »îÀÇ Áú °³¼±À» ½ÇÇöÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀåÀº ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀå¿¡¼­ »óÈ£ ¿¬°üµÈ ¿©·¯ ¿äÀο¡ ÀÇÇØ °­·ÂÇÑ ¼ºÀå µ¿·ÂÀ» º¸À̰í ÀÖ½À´Ï´Ù. ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â Áø´Ü ±â¼ú Çâ»ó°ú ½Å»ý¾Æ ¼±º°°Ë»ç ÇÁ·Î±×·¥ È®´ë¿¡ µû¸¥ À¯Àü¼º ÃâÇ÷¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¸¦ µé ¼ö ÀÖÀ¸¸ç, ÀÌ´Â Á¶±â ¹ß°ß ¹× Ä¡·á ½ÃÀÛÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ ±â¼úÀû ¹ßÀüÀº Ä¡·á ÆÐ·¯´ÙÀÓ¿¡ Çõ¸íÀ» °¡Á®¿Ô°í, ¹Ý°¨±â°¡ ¿¬ÀåµÈ À¯ÀüÀÚ ÀçÁ¶ÇÕ ÀÎÀÚÀÇ °³¹ßÀº ÁÖ»ç Ƚ¼ö¸¦ ÁÙÀ̰í ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ô¿´À¸¸ç, ¿¡¹Ì½ÃÁÖ¸¿°ú °°Àº »õ·Î¿î ºñÀÎÀÚ ¿ä¹ýÀº ¾ïÁ¦Á¦ ȯÀÚ¿¡°Ô ´ëü Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ½ÅÈï±¹À» Áß½ÉÀ¸·Î ÇÑ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ÀÎ½Ä °³¼± Ä·ÆäÀÎ ¹× ȯÀÚ Áö¿ø Ȱµ¿ÀÇ È°¼ºÈ­°¡ ¸Â¹°·Á ½ÃÀå Á¢±Ù¼ºÀÌ È®´ëµÇ°í, ÷´Ü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Èñ±ÍÁúȯ ¿¬±¸ ¹× Èñ±ÍÁúȯ Ä¡·áÁ¦ °³¹ßÀ» Áö¿øÇÏ´Â Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê´Â ±ÔÁ¦ ÇýÅðú ½Å¼ÓÇÑ ½ÂÀÎ °æ·Î¸¦ ÅëÇØ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ³óÃàÀÎÀÚ Á¦Á¦ ¹× °í±Þ Ä¡·áÁ¦¿¡ ¼Ò¿äµÇ´Â ¸·´ëÇÑ ºñ¿ëÀÌ ½ÃÀåÀÇ Å« ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­´Â Á¢±Ù¼ºÀÌ Á¦ÇѵǾî ÀÇ·á ½Ã½ºÅÛ¿¡ Å« °æÁ¦Àû ºÎ´ãÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÁßÁõ Ç÷¿ìº´ A ȯÀÚÀÇ ¾à 25-30%¿¡¼­ ÁßÈ­Ç×ü(¾ïÁ¦Á¦)°¡ °³¹ßµÇ¾î Ä¡·áÀü·«ÀÌ º¹ÀâÇØÁö°í Ä¡·áºñ¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÅÈï±¹ ½ÃÀåÀÇ ³·Àº ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü ÀÎÁöµµ, Á¦Ç° À¯ÅëÀ» À§ÇÑ ÄݵåüÀÎ ÀÎÇÁ¶ó ¹Ìºñ, ¼­·Î ´Ù¸¥ ½ÃÀå °£ÀÇ º¹ÀâÇÑ ±ÔÁ¦´Â ¶Ç ´Ù¸¥ µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. Ç÷Àå À¯·¡ Á¦Ç°°ø±Þ¸Á È¥¶õ°ú Ç÷Àå ºÎÁ·Àº ½ÃÀåÀÇ ºÒ¾ÈÁ¤¼ºÀ» ¾ß±âÇϰí ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, ÀáÀçÀûÀÎ ±â´ÉÀû Ä¡·á¹ý°ú Àå±âÀûÀ¸·Î ºñ¿ë ´ëºñ È¿°ú°¡ ±â´ëµÇ´Â À¯ÀüÀÚ Ä¡·áÁ¦ÀÇ °³¹ßÀÌ È®´ëµÇ¸é¼­ Å« ºñÁî´Ï½º ±âȸ°¡ âÃâµÇ°í ÀÖ½À´Ï´Ù. °³ÀÎÈ­µÈ ÀÇ·á Á¢±Ù ¹æ½Ä¿¡ ´ëÇÑ °ü½É Áõ°¡, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀ» À§ÇÑ ¿ø°Ý ÀÇ·á ÅëÇÕ, ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× Áß³²¹Ì ½ÃÀå¿¡¼­ÀÇ ÇコÄɾî ÀÎÇÁ¶ó ÅõÀÚ Áõ°¡´Â ½ÃÀå È®´ëÀÇ Å« ÀáÀç·ÂÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

º» º¸°í¼­ÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå ºÐ¼® ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦ ¹× µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀå, Áúȯ À¯Çüº°(2020-2032³â)

Á¦5Àå ¼¼°èÀÇ ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀå, Ä¡·á À¯Çüº°(2020-2032³â)

Á¦6Àå ¼¼°èÀÇ ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀå : Á¦Çüº°(2020-2032³â)

Á¦7Àå ¼¼°èÀÇ ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀå : Åõ¿© °æ·Îº°(2020-2032³â)

Á¦8Àå ¼¼°èÀÇ ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀå : ¿¬·ÉÃþº°(2020-2032³â)

Á¦9Àå ¼¼°èÀÇ ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°(2020-2032³â)

Á¦10Àå ¼¼°èÀÇ ÀÀ°íÀÎÀÚ °áÇÌÁõ ½ÃÀå : Áö¿ªº°(2020-2032³â)

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È

Á¦13Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Coagulation Factor Deficiency Market is estimated to be valued at USD 5.01 Bn in 2025 and is expected to reach USD 8.90 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.2% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 5.01 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.20% 2032 Value Projection: USD 8.90 Bn

The global coagulation factor deficiency market represents a critical segment within the broader hematology therapeutics landscape, addressing rare but life-threatening inherited bleeding disorders characterized by the absence or dysfunction of specific clotting factors essential for normal hemostasis. Coagulation factor deficiencies encompass a spectrum of conditions including hemophilia A (Factor VIII deficiency), hemophilia B (Factor IX deficiency), and rarer deficiencies involving factors I, II, V, VII, X, XI, and XIII, collectively affecting approximately 400,000 individuals worldwide.

These disorders manifest through prolonged bleeding episodes, spontaneous hemorrhages, and increased surgical risks, necessitating lifelong management through factor replacement therapies, prophylactic treatments, and emerging gene therapies. The market has witnessed substantial evolution from plasma-derived concentrates to recombinant factors and extended half-life products, driven by technological advancements and improved understanding of coagulation cascade mechanisms. Rising awareness among healthcare professionals, enhanced diagnostic capabilities, improved patient registries, and expanding access to specialized care in developing regions contribute to market growth. The therapeutic landscape continues to transform with innovative approaches including non-factor therapies, subcutaneous formulations, and gene editing technologies, offering enhanced convenience and improved quality of life for patients while addressing the substantial economic burden associated with these chronic conditions.

Market Dynamics

The global coagulation factor deficiency market demonstrates robust growth dynamics driven by multiple interconnected factors that shape its trajectory across developed and emerging markets. Primary market drivers include the increasing prevalence of inherited bleeding disorders due to improved diagnostic techniques and expanded newborn screening programs, which enhance early detection and treatment initiation. Technological advancements in biotechnology have revolutionized treatment paradigms, with the development of extended half-life recombinant factors reducing injection frequency and improving patient compliance, while novel non-factor therapies like emicizumab provide alternative treatment options for patients with inhibitors. Rising healthcare expenditure, particularly in emerging economies, coupled with growing awareness campaigns and patient advocacy initiatives, expands market accessibility and drives demand for advanced therapeutics. Government initiatives supporting rare disease research and orphan drug development, including regulatory incentives and expedited approval pathways, further stimulate market growth. However, significant market restraints persist, primarily centered around the prohibitive cost of factor concentrates and advanced therapies, which limit accessibility in resource-constrained settings and create substantial financial burden on healthcare systems. The development of neutralizing antibodies (inhibitors) in approximately 25-30% of severe hemophilia A patients complicates treatment strategies and increases therapeutic costs. Limited awareness among healthcare providers in developing regions, inadequate cold chain infrastructure for product distribution, and regulatory complexities across different markets pose additional challenges. Supply chain disruptions and plasma shortages for plasma-derived products create market volatility. Nevertheless, substantial opportunities emerge from expanding gene therapy developments, which promise potential functional cures and long-term cost-effectiveness. Growing focus on personalized medicine approaches, telemedicine integration for remote patient monitoring, and increasing healthcare infrastructure investments in Asia Pacific and Latin American markets present significant growth potential for market expansion.

Key Features of the Study

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Coagulation Factor Deficiency Market, By Disorder Type, 2020-2032, (USD Bn)

5. Global Coagulation Factor Deficiency Market, By Treatment Type, 2020-2032, (USD Bn)

6. Global Coagulation Factor Deficiency Market, By Dosage Form, 2020-2032, (USD Bn)

7. Global Coagulation Factor Deficiency Market, By Route of Administration, 2020-2032, (USD Bn)

8. Global Coagulation Factor Deficiency Market, By Age Group, 2020-2032, (USD Bn)

9. Global Coagulation Factor Deficiency Market, By End User, 2020-2032, (USD Bn)

10. Global Coagulation Factor Deficiency Market, By Region, 2020 - 2032, Value (USD Bn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â